PE20091968A1 - Inhibidores de las jnk - Google Patents

Inhibidores de las jnk

Info

Publication number
PE20091968A1
PE20091968A1 PE2009000646A PE2009000646A PE20091968A1 PE 20091968 A1 PE20091968 A1 PE 20091968A1 PE 2009000646 A PE2009000646 A PE 2009000646A PE 2009000646 A PE2009000646 A PE 2009000646A PE 20091968 A1 PE20091968 A1 PE 20091968A1
Authority
PE
Peru
Prior art keywords
lower alkyl
ilamino
ilo
indol
pyrimidin
Prior art date
Application number
PE2009000646A
Other languages
English (en)
Inventor
Humberto Bartolome Arzeno
James Patrick Dunn
David Michael Goldstein
Leyi Gong
Xiaochun Han
Joan Heather Hogg
Alam Jahangir
Wylie Solang Palmer
Deborah Carol Reuter
Tania Silva
Parcharee Tivitmahaisoon
Teresa Alejandra Trejo-Martin
Shao-Yong Wu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20091968A1 publication Critical patent/PE20091968A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I), DONDE R1 Y R2 SON CADA UNO H, ALQUILO INFERIOR, ENTRE OTROS; R3 ES H, NH2, NCH3, ENTRE OTROS; Q ES CH, N; Z1 ES (CH2)u; Z2 ES (CH2)v; X1, X2 Y X3 SON CADA UNO ALQUILO INFERIOR, ALCOXI INFERIOR, HALOALCOXI INFERIOR, HIDROXI; X4 Y X5 SON CADA UNO ALQUILO INFERIOR, ALCOXI INFERIOR, HIDROALQUILO, ENTRE OTROS; m, q Y r SON CADA UNO 0-2; n, p, u Y v SON CADA UNO 0-1; Y1 ES CH3, ALQUILO INFERIOR; Y2 ES H, ALQUILO INFERIOR, HALOALQUILO INFERIOR, HETEROALQUILO INFERIOR, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (S)-2-AMINO-PROPIONATO DE 1-(4-{4-[4-(3-METANOSULFONIL-PROPOXI)-INDOL-1-IL]-PIRIMIDIN-2-ILAMINO}-CICLOHEXANOCARBONIL)-PIPERIDIN-4-ILO, (2R,3R)-2-(TERT-BUTOXICARBONIL-METIL-AMINO)-3-METIL-PENTANOATO DE 1(4-{4-[4-(3-METANOSULFONIL-PROPOXI)-INDOL-1-IL]-PIRIMIDIN-2-ILAMINO}-CICLOHEXANOCARBONIL)-PIPERIDIN-4-ILO, ENTRE OTROS. TAMBIEN SE REFIERE A UN METODO DE PREPARACION Y UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS INHIBEN LAS JNK (QUINASAS C-JUN-N-TERMINALES), SIENDO UTILES EN EL TRATAMIENTO DE TRASTORNOS INFLAMATORIOS ARTRITIS REUMATOIDE Y ASMA
PE2009000646A 2008-05-16 2009-05-12 Inhibidores de las jnk PE20091968A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5389608P 2008-05-16 2008-05-16

Publications (1)

Publication Number Publication Date
PE20091968A1 true PE20091968A1 (es) 2010-01-15

Family

ID=40937466

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000646A PE20091968A1 (es) 2008-05-16 2009-05-12 Inhibidores de las jnk

Country Status (18)

Country Link
US (1) US8183254B2 (es)
EP (1) EP2283009B1 (es)
JP (1) JP5329648B2 (es)
KR (1) KR101368079B1 (es)
CN (1) CN102015689B (es)
AR (1) AR071789A1 (es)
AU (1) AU2009248233A1 (es)
BR (1) BRPI0912564A2 (es)
CA (1) CA2722158A1 (es)
CL (1) CL2009001192A1 (es)
ES (1) ES2392788T3 (es)
IL (1) IL208916A0 (es)
MX (1) MX2010012249A (es)
PE (1) PE20091968A1 (es)
RU (1) RU2504545C2 (es)
TW (1) TW200948804A (es)
WO (1) WO2009138340A1 (es)
ZA (1) ZA201007178B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102918035B (zh) * 2010-06-04 2015-05-27 霍夫曼-拉罗奇有限公司 用作jnk的抑制剂的2-氨基-嘧啶衍生物
KR20130091308A (ko) * 2010-06-04 2013-08-16 에프. 호프만-라 로슈 아게 Jnk 억제제
US10190096B2 (en) 2014-12-18 2019-01-29 President And Fellows Of Harvard College Methods for generating stem cell-derived β cells and uses thereof
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
WO2017204626A1 (en) 2016-05-24 2017-11-30 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Combination therapy - combined map2k4/map3k1 and mek/erk inhibition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383546A1 (en) * 1999-06-30 2001-01-04 William H. Parsons Src kinase inhibitor compounds
US7314878B2 (en) * 2002-04-25 2008-01-01 Laboratories Serono Sa Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or CNS disorders
WO2006038001A1 (en) * 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
GB0500492D0 (en) * 2005-01-11 2005-02-16 Cyclacel Ltd Compound
CA2662998C (en) 2006-09-08 2015-10-06 F. Hoffmann-La Roche Ag Benzotriazole kinase modulators
AU2007328981B2 (en) * 2006-12-08 2013-07-11 F. Hoffmann-La Roche Ag Substituted pyrimidines and their use as JNK modulators

Also Published As

Publication number Publication date
AU2009248233A1 (en) 2009-11-19
KR20100137567A (ko) 2010-12-30
EP2283009B1 (en) 2012-08-29
US8183254B2 (en) 2012-05-22
CL2009001192A1 (es) 2010-08-13
EP2283009A1 (en) 2011-02-16
ES2392788T3 (es) 2012-12-13
AR071789A1 (es) 2010-07-14
RU2504545C2 (ru) 2014-01-20
WO2009138340A1 (en) 2009-11-19
JP5329648B2 (ja) 2013-10-30
CN102015689A (zh) 2011-04-13
MX2010012249A (es) 2010-12-06
KR101368079B1 (ko) 2014-03-14
CN102015689B (zh) 2014-01-08
ZA201007178B (en) 2013-03-27
BRPI0912564A2 (pt) 2019-09-24
JP2011520824A (ja) 2011-07-21
RU2010151475A (ru) 2012-06-27
CA2722158A1 (en) 2009-11-19
US20090318484A1 (en) 2009-12-24
TW200948804A (en) 2009-12-01
IL208916A0 (en) 2011-01-31

Similar Documents

Publication Publication Date Title
PE20110598A1 (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
PE20141120A1 (es) Compuestos heterociclicos
TN2014000033A1 (fr) Indazoles
AR074306A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes
EA201070698A1 (ru) Твердые формы 3-(6-(1-(2,2-дифторбензо[d][1,3]-диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
PE20060373A1 (es) Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2
DK2091948T3 (da) Nye inhibitorer af glutaminylcyclase
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
PE20091968A1 (es) Inhibidores de las jnk
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
PE20081120A1 (es) Derivados de hidantoina como inhibidores de metaloproteinasas de matriz (mmp)
PE20080856A1 (es) Inhibidores de metaloproteasas de matriz
PE20070619A1 (es) TIENO(2,3-b)PIRIDIN-5-CARBONITRILOS COMO INHIBIDORES DE PROTEINAS QUINASA
PE20141380A1 (es) Imidazopiridazinas como inhibidores de quinasa akt
PE20091400A1 (es) Derivados de n-(2-amino-fenil)-amida como inhibidores de hdac
PE20150224A1 (es) Inhibidores del nampt
CO6341581A2 (es) Derivados de heteroarilo como inhibidores de dgat1
EA201171211A1 (ru) Производные оксадиазола
PE20080453A1 (es) Derivados de fenil.oxi-fenil-pirimidinona en el tratamiento de malaria
PE20110433A1 (es) Antagonistas de la via hedgehog de ftalazina disustituida
PE20091579A1 (es) Derivados de sulfonamida sustituida
EA201070779A1 (ru) Триазолсодержащие производные оксадиазола
PE20070173A1 (es) Compuestos de indol carboxamidas como inhibidores de ikk2
MX350862B (es) Acidos de piperidinil naftilacetico.
EA201071269A1 (ru) 3,4-замещенные пиперидиновые производные в качестве ингибиторов ренина

Legal Events

Date Code Title Description
FD Application declared void or lapsed